Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade

Hims & Hers Health (HIMS) shares underperformed in the latest trading session, closing down 2.83% while major indices rose. Despite this, the company anticipates strong growth, with projected EPS of $0.17, a 183.33% increase year-over-year, and quarterly revenue of $551.84 million, up 74.83% from the prior year; full-year revenue is projected to increase by 58.31%. HIMS currently holds a Zacks Rank #2 (Buy), reflecting upward revisions in analyst estimates, though its forward P/E ratio of 77.39 represents a premium compared to the industry average of 27.09.

Analysis

Hims & Hers Health, Inc. (HIMS) recently experienced a share price decline, closing at $55.25, a 2.83% decrease, which notably lagged the S&P 500's 0.55% gain on the same day. Over the preceding month, HIMS shares appreciated by 2.99%, underperforming both the S&P 500's 6.29% advance and the Medical sector's 3.49% gain. Despite this recent market underperformance, the company's forward-looking financial projections are exceptionally strong. Upcoming quarterly Earnings Per Share (EPS) is forecasted at $0.17, marking a substantial 183.33% increase year-over-year, while quarterly revenue is anticipated to reach $551.84 million, a 74.83% rise from the year-ago period. For the full fiscal year, consensus estimates point to earnings of $0.73 per share, a 170.37% increase, and revenue of $2.34 billion, up 58.31% from the prior year. Supporting this optimistic outlook, the Zacks Consensus EPS estimate has seen a 5.66% upward revision in the past month, contributing to HIMS's current Zacks Rank #2 (Buy). From a valuation standpoint, HIMS trades at a Forward P/E ratio of 77.39, a significant premium compared to its industry's average of 27.09. However, its PEG ratio stands at 2.12, aligning with the Medical Info Systems industry average, suggesting the high P/E might be rationalized by its strong earnings growth expectations. The Medical Info Systems industry itself demonstrates relative strength, holding a Zacks Industry Rank of 70, placing it in the top 29% of over 250 industries.

Key Decisions for Investors

• Investors should meticulously evaluate the upcoming earnings release to ascertain if the company achieves its aggressive growth projections, particularly the 183.33% EPS increase and 74.83% revenue growth, which are crucial for sustaining its current valuation.
• The current Zacks Rank #2 (Buy) and positive analyst estimate revisions signal underlying business strength, but these must be weighed against the elevated Forward P/E ratio of 77.39; the PEG ratio of 2.12 offers some justification for this premium if growth materializes as projected.
• Consider the recent share price dip as a potential entry point for investors with a tolerance for higher valuation risk, contingent on the confirmation of sustained high growth in the forthcoming financial results.